NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on March 11, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
Date: | Monday, March 11th |
Time: | 4:30 p.m. Eastern time |
Toll-Free Dial-In: | 1-877-704-4453 |
International Dial-In: | 1-201-389-0920 |
Conference ID: | 13743864 |
Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to top-notch and affordable care. For more information, please visit LifeMD.com.
Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.79 |
Daily Change: | 0.35 5.43 |
Daily Volume: | 2,215,653 |
Market Cap: | US$321.980M |
September 18, 2025 August 05, 2025 July 31, 2025 May 22, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load